- Broadens Scope in Singapore to Include Development and
- Celebrates Formation of EPIC Bio, a Joint Venture with Temasek Life
SINGAPORE & ROCKVILLE, Md., Oct 08, 2010 (BUSINESS WIRE) --
Emergent BioSolutions Inc. (NYSE:EBS), a U.S.-based developer and
manufacturer of vaccines and antibody therapies, today launched its
Singapore operations. The opening event included a ceremonial unveiling
of EPIC Bio Pte Ltd that took place at Temasek Life Sciences Laboratory
(TLL) in Singapore. EPIC Bio is a recently formed Singapore-based joint
venture with Temasek Life Sciences Ventures Pte Ltd (TLV), to develop,
manufacture, and commercialize pandemic influenza vaccines and
"Emergent is pleased to enhance its presence in Asia-Pacific with
initiatives that help carry out our corporate mission -- to protect
life," said Fuad El-Hibri, Chairman and CEO of Emergent BioSolutions.
"First, by broadening the scope of Emergent's Singapore operations, not
only will it continue to make our present and future biodefense products
available, but it will also provide support to the company's ongoing
tuberculosis program as well as explore manufacturing and business
development opportunities in the region. Second, by forming EPIC Bio
with TLV, Emergent leverages important technology and product
development know how to complement TLL's research and development
efforts in pandemic influenza."
"Emergent BioSolutions' expansion of its Singapore office and R&D
activities here attest to Singapore's importance as a core site in Asia
for both leading pharmaceutical and biotech companies. In leveraging
Singapore's integrated research network and business capabilities,
companies are well-positioned to develop new therapies and business
models for the future today," said Mr. Quek Swee Kuan, Assistant
Managing Director, Singapore Economic Development Board.
"Emergent BioSolutions provides vaccines that protect our servicemen and
women in the U.S. military against the threat of anthrax," said Louis
Mazel, Deputy Chief of Mission, U.S. Embassy in Singapore. "We are
pleased that they are also involved in the development of products for
other deadly diseases including tuberculosis and influenza supporting
their corporate mission of protecting life."
The event also featured Professor Jimmy Kwang, Senior Principal
Investigator at Temasek Life Sciences Laboratory, who presented current
TLL efforts on influenza research. "The field of influenza vaccine and
therapeutic research is challenging," said Professor Kwang. "We have
made strides in progressing a broad spectrum influenza vaccine candidate
designed to provide maximum coverage of influenza strains."
Emergent's Singapore office will provide support to EPIC Bio as the
joint venture builds out its operations. EPIC Bio plans to begin
clinical manufacturing of a broad spectrum influenza vaccine candidate
in 2011 and to initiate a clinical trial in 2012.
Dr. Tan Guong Ching, Chairman of TLV, and representatives from the
American Chamber of Commerce in Singapore were also present at the
event. In a separate celebration, Emergent held a ribbon cutting
ceremony at its Singapore office attended by Emergent executives, and
members of the diplomatic and business community.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information about the company may be found at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding strategy, future operations, future financial
position, future revenues, projected costs, future product development,
prospects, plans and objectives of management, and any other statements
containing the words "believes", "expects", "anticipates", "plans",
"estimates" and similar expressions, are forward-looking statements.
There are a number of important factors that could cause the actual
results of the Consortium or Emergent to differ materially from those
indicated by such forward-looking statements, including the timing of,
and the potential for successful outcomes resulting from, future product
development efforts; the ability of the Consortium or Emergent to obtain
funding for product development efforts; plans of the Consortium and
Emergent to expand manufacturing facilities and capabilities; the rate
and degree of market acceptance and clinical utility of products; and
other factors identified in Emergent's Quarterly Report on Form 10-Q for
the quarter ended June 30, 2010 and subsequent reports filed with the
SEC. The Consortium and Emergent disclaim any intention or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this press release.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications